{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.1",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "De Felice2008",
      "version": "1.0.0",
      "authors": "Rana Aldisi",
      "description": "This document contains the bel code for the Article Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers by De Felice et al"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/cf4d8bb88754f036b943b4d94ad96e103dcb7149/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/hbp-knowledge/hbp_knowledge/defelice2008.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "LY294002",
      "id": "59d55e7fbc9f6ab21fe25d8207c3cf38ca7257a8c70e06ea9d72deb9682098f07c20990b576a320fe6e79e6d4292322f1d3f2e53d4fd4a527f0bb489a20d5cd4"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "synapse",
      "id": "cc12602eef45267795bef1781b57fdcfc0800fd22ea1a8c57746d2be9789ec52c582f9244ba1318f068bf1cfa150d96ad79553596c1e96633df8fa625ad1af74"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta antibody, NU1",
      "id": "a29a235bd4cb1e77c9c01542986b531e9ed9f3a3a90066bd7ebcc8a9806fa43f01065ce178e2d7e145b54c0ca11ab0faec08500c6978933862f9a9ff2794dbbb"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta derived diffusible ligands",
      "id": "bb1bf00d89b855bbc846286bc0389eba22194342acf023f66bc324ceacf0ba483cee9dc67d56822bb7efa028804229cb820f4c45346b8131ec4cc58b8ff7f06a"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta fibrils",
      "id": "67b4c76bd9f06b116883a58eaa40e8453f2fda318ae9313477ebc24c6d04613ea373fdf611fd8a740de5a090826662d88c39f2ab166bca226cc8237cb0c71a1a"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta oligomers",
      "id": "a0fc661406161db12bdd89333a13d0ee89b3aa089d5eb16676962cae3efd25d4d3dd6e593dbcaebf5fc0c26f9c8c070a98f2ff0fb94a0d52412c0fa0bf6c5b3b"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine",
      "id": "974e7ea9cc24b53a13a49a8b96f777bd1ad3ae7e05c95f6d5961be51aa632c5384005c993a0b73c10f9450c1ec83f053668bbd613052a502083874397f2e5779"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Neurons",
      "id": "130131072f276d163b9e361a4ca4814f1d254907d297db502ccb4f6e75dff10db1f2b384bb435c9b46e91310d585aea1db3108e00905a31bb1388ccda1f0c643"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "signal transduction",
      "id": "d3608eaee3f25f464803835ebd517e72f6846b665d75d61b45c66a6b129b218063af2c786170c0ce992cee3a5dbad92aa0cc0ab20038b430436f70147d366e4f"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Cell Survival",
      "id": "abeaa000ab588015eac485dd605b78602795a7e237f3b097d8148a27fa3ebcc7a221d318d0399960d9f10cf194fbc9c29f41a2a8ed8c332b09f4b79680170b61"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "GO",
          "name": "synapse",
          "id": "cc12602eef45267795bef1781b57fdcfc0800fd22ea1a8c57746d2be9789ec52c582f9244ba1318f068bf1cfa150d96ad79553596c1e96633df8fa625ad1af74"
        },
        {
          "function": "Abundance",
          "namespace": "HBP",
          "name": "amyloid-beta derived diffusible ligands",
          "id": "bb1bf00d89b855bbc846286bc0389eba22194342acf023f66bc324ceacf0ba483cee9dc67d56822bb7efa028804229cb820f4c45346b8131ec4cc58b8ff7f06a"
        }
      ],
      "id": "519ea85a656b0fa5394d9cad7ef962680c9df9dbfa8347f2aa5c9a4421566bea8ed4f2f1445a82cedb704d7f359af12a57afb3ee84a2b4900e6111eed43f67a1"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "HBP",
          "name": "amyloid-beta derived diffusible ligands",
          "id": "bb1bf00d89b855bbc846286bc0389eba22194342acf023f66bc324ceacf0ba483cee9dc67d56822bb7efa028804229cb820f4c45346b8131ec4cc58b8ff7f06a"
        },
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "Neurons",
          "id": "130131072f276d163b9e361a4ca4814f1d254907d297db502ccb4f6e75dff10db1f2b384bb435c9b46e91310d585aea1db3108e00905a31bb1388ccda1f0c643"
        }
      ],
      "id": "583b73bbe09814f4b5125e51c9cbdcab4d9ce3ec0698793bc047b2810f9c6ad400dd71ec532ef1adf63409ac0d95258ca4b99f5053de46cb92dddf24da3324cb"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "HBP",
          "name": "amyloid-beta derived diffusible ligands",
          "id": "bb1bf00d89b855bbc846286bc0389eba22194342acf023f66bc324ceacf0ba483cee9dc67d56822bb7efa028804229cb820f4c45346b8131ec4cc58b8ff7f06a"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
        }
      ],
      "id": "89b26633e25e6cc1b729314c465b6e5b8d5c259712d38d46d3504562484ffd6445c5fa0443b28c58c0acab4336029eb1cfa4d1b45a8e58e7000059019c956d21"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "hyperphosphorylation"
          }
        }
      ],
      "id": "ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 404
        }
      ],
      "id": "a448f901ddc919f32d50fa5284355b4eb4ed52e9ebf8705052086706d728d8ebef0cc66616b7fbfda3aeffd49db6e41134fb39996aa9b996a73bce331de95767"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 181
        }
      ],
      "id": "820b780f4d0abcec3e7acc5219d0bf0d994ff6274f5579982e73ee0337a49544a879a9cfee0a37d3bd9d93b5e34382eb0c319ef7f7c31ff6f74841594b6fb17a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 231
        }
      ],
      "id": "fd67fbe5c0c0911e8bffaf415eb40748a781d8776f2e2cdf8a3f4f97f0f2f312aaa680c7b670dc27b11d220f0079b4d5e41cbcf095a568bc644b6e9eaefc50b3"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "id": "d7ee72cc866dbe8148a83717b5c56b67f46b715c1c11fac47257b38efabf4f3947f73dc4a227db3e8e7a2039b162b0b1b1bbb0d7605e6e651f1dba7fedfc3bd4"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "3b0967909beeb3e40181b42fd6d8b686507dc30354899f69d27bf9a7ea2017d23c8c8eacece7f76cec5a6edf1718c6a64dcbe256459eaf7543b8049d477f0c96"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "Neurodegeneration",
      "id": "1e32e61de82d42fab0a4abcd15d32d3fa5b2f65883b2d99c828d4019591a465f11cd017eefe918bc5d066b7f3cef9d21f4e0988e5c23cc2c135313815478263a"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    }
  ],
  "links": [
    {
      "line": 92,
      "relation": "decreases",
      "evidence": "At longer incubation times (48 and 96 h) ADDLs caused a progressive decrease in MTT reduction (Fig. 1B), which can be due to altered trafficking (Liu et al., 1998) as well as cell death.",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 3,
      "target": 9,
      "key": "c85962e184dc952c4abd008ac94bf9ef67101f41de05097d317600aff33eba1fd7fee06d25e0675374bac30085859ec1e4f661547d7ed39659a092f87a7a6526"
    },
    {
      "line": 100,
      "relation": "increases",
      "evidence": "While vehicle treated cells (Fig. 2A and B) exhibited low phosphotau immunofluorescence, cells treated with 1 microM biotinylated ADDLs (bADDLs) for 6 h (Fig. 2C and D) showed a significant increase in P-tau immunofluorescence (Fig. 2D).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 3,
      "target": 15,
      "key": "27550a8bbd22585883ad46d3b1ab603e9546a1f5dbff8c510112dd47ce57b4ff05d4b0238b1eac406d61361e9f34d5c7d625fa8f15c238b04bebf31708f9c697"
    },
    {
      "line": 115,
      "relation": "increases",
      "evidence": "We then investigated whether bADDLs also induced tau phosphorylation in rat hippocampal neurons. To this end, we initially used frozen dissociated rat hippocampal cell preparations (Cambrex). Cells were maintained in the presence of 1\u0003M bADDLs (Fig. 2I and J) or vehicle (not shown) for 6 h at 37 ◦C. We observed a marked P-tau immunostaining in a subpopulation of neurons that also had ADDLs bound (Fig. 2I, arrowheads), while cells that did not bind bADDLs had no AT8 staining (Fig. 2J).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "Species": {
          "10116": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 3,
      "target": 20,
      "key": "28f5bc0a6eab27dd9fc66e67a2e214d424be7bc9f4376332de1307ac0c596b46d7cd255cb07a16d332aaa405ebc5e206f7ba61fe96aebabf9b549b4eacde145f"
    },
    {
      "line": 130,
      "relation": "increases",
      "evidence": "Following exposure to ADDLs, double-label immunofluorescence microscopy showed high levels of tau phosphorylated at Thr231, which discriminates among AD and non-AD subjects and patients with other forms of dementia (Hampel et al., 2004, 2003), in neurons with prominent dendritic ADDL binding (detected with NU1, Fig. 2K–M). ADDL binding to synaptic hot-spots in hippocampal neurons is evident in images at highermagnification (60×objective, PanelsLand M).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 3,
      "target": 18,
      "key": "bf0981345576e41154409d42cd8cfd44fc4184379a66b25f7fbb1cda08cdf69b3617b6b024c1d454ffdf4831e2453a6070a4cfd82a5c5b669d502bf8d3647a28"
    },
    {
      "line": 157,
      "relation": "increases",
      "evidence": "Vehicle-treated neurons (Fig. 3A and E) exhibited very low phosphotau immunofluorescence, but neurons treated for 4 h with 500nM ADDLs showed significantly higher levels in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3B and F, respectively). Neurons treated for 4 h with 10\u0003M Abeta fibrils also showed an increase in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3C and G, respectively).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 3,
      "target": 18,
      "key": "0f18a1df583638d89f5ff6f7c85b29127d600789b3ed6f6d8f5f508aba63ec5a79779c43275e713efa62469db1b572be549069558f19efc8e0374f3604e8a498"
    },
    {
      "line": 191,
      "relation": "increases",
      "evidence": "Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \u0003M Abeta fibrils (Fig. 4A–D).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 3,
      "target": 18,
      "key": "91054ea23c9c265fd7ab636a81d0ee4a475ccca92b389d51f0b2f28d838abd26838ddaa1805ae198cd0cfb45b5e80fd34a1a8af104139bce9854496960d30a80"
    },
    {
      "line": 135,
      "relation": "increases",
      "evidence": "Following exposure to ADDLs, double-label immunofluorescence microscopy showed high levels of tau phosphorylated at Thr231, which discriminates among AD and non-AD subjects and patients with other forms of dementia (Hampel et al., 2004, 2003), in neurons with prominent dendritic ADDL binding (detected with NU1, Fig. 2K–M). ADDL binding to synaptic hot-spots in hippocampal neurons is evident in images at highermagnification (60×objective, PanelsLand M).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 3,
      "target": 10,
      "key": "1d92a18555986dccb6ee7634b97317900eed84a4262d0ae015517d30da4380eecde012c78a5cb379e86abdfc3b60587536dcdc1b85ea79e064dbf95cbfa41010"
    },
    {
      "line": 158,
      "relation": "increases",
      "evidence": "Vehicle-treated neurons (Fig. 3A and E) exhibited very low phosphotau immunofluorescence, but neurons treated for 4 h with 500nM ADDLs showed significantly higher levels in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3B and F, respectively). Neurons treated for 4 h with 10\u0003M Abeta fibrils also showed an increase in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3C and G, respectively).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 3,
      "target": 16,
      "key": "695fdc419674b27587af742857a27d2c3c2c85e249aa1660c0c84e9c69c4af10f5330b09be650bf625549b69614a81d8659ae05d3446e867b9fdb747a5703122"
    },
    {
      "line": 192,
      "relation": "increases",
      "evidence": "Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \u0003M Abeta fibrils (Fig. 4A–D).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 3,
      "target": 16,
      "key": "a9d7f4f0fa0bd522c0d3ec991f4bcedaf82529386b97eb60b09c846e4f3414712a829547554b6946a298681180c37574a46ec63bd933a65f6834cbce83f9246c"
    },
    {
      "line": 193,
      "relation": "increases",
      "evidence": "Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \u0003M Abeta fibrils (Fig. 4A–D).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 3,
      "target": 17,
      "key": "a53269b73f212b1f730d967ef62be2db16511891c1479b236a625e6d2f648155a085ec5a5ae796e9eceb4de46fb1687edf6080ea2d239c9db056ccc53c536aba"
    },
    {
      "line": 181,
      "relation": "positiveCorrelation",
      "evidence": "We note that these observed increases in tau phosphorylation occurred well before neuronal death (Fig. 1B), consistent with this pathology representing an early stage in neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 15,
      "target": 21,
      "key": "2d38c498c13733e6c4949230c5bb69a6d4b4a6b445d04d26bae6eef365a42e7fcfb57fe86a5a5e22563fb891c5f97cfb8edc25134b07ca41ac7614c1b275c4d9"
    },
    {
      "relation": "hasVariant",
      "source": 13,
      "target": 15,
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48"
    },
    {
      "relation": "hasVariant",
      "source": 13,
      "target": 18,
      "key": "43f3a05a562aea7d640aaac845125159fcfbdd06303b001b5cf1eec04af58dabda000353c3cf4551bae1aea91c8b1be6e3f2669e44287e4a25d0655b1d33aab4"
    },
    {
      "relation": "hasVariant",
      "source": 13,
      "target": 16,
      "key": "50403cc7ef5ce4172930d644a5740cda8918061439e7d529c0f888ba1b049a77a5339ec7d3482657b832429d9e62714c7fafa0d13366824ad8debfc61eaefc20"
    },
    {
      "relation": "hasVariant",
      "source": 13,
      "target": 14,
      "key": "9fbd9218812f1cd82827e2d73f3b6af04acbe1f408aaedcdc53c6fc17a36272c67cdcc254874f5473ba4443fa19971fe4877420e735c04f4f7353480d8e1f8b2"
    },
    {
      "relation": "hasVariant",
      "source": 13,
      "target": 17,
      "key": "213a46846a62680cc05d2ed2719a937dff6a8fabf62eab17e78a50282285efef229adb3605d9160e01e020062742249185e5f3756340776a7a7cac3951c27468"
    },
    {
      "relation": "hasVariant",
      "source": 19,
      "target": 20,
      "key": "13dfd5e324e943b5b15969ee80cc94c2ee476ba98038149d2d3eea748cda06d59bc0296a07e95ac18a414ec8c83ff561354f04122550f1c3479a8907fea110a6"
    },
    {
      "line": 131,
      "relation": "positiveCorrelation",
      "evidence": "Following exposure to ADDLs, double-label immunofluorescence microscopy showed high levels of tau phosphorylated at Thr231, which discriminates among AD and non-AD subjects and patients with other forms of dementia (Hampel et al., 2004, 2003), in neurons with prominent dendritic ADDL binding (detected with NU1, Fig. 2K–M). ADDL binding to synaptic hot-spots in hippocampal neurons is evident in images at highermagnification (60×objective, PanelsLand M).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 18,
      "target": 22,
      "key": "aaae49fe5a08e80b8e3b1a34b5029df6fe6da6174f5988892eed8f7fbc23f8b6793c6f42f89f8823c179ae81e22e447d085d87ebcec59752ec155197a795bca8"
    },
    {
      "line": 131,
      "relation": "positiveCorrelation",
      "evidence": "Following exposure to ADDLs, double-label immunofluorescence microscopy showed high levels of tau phosphorylated at Thr231, which discriminates among AD and non-AD subjects and patients with other forms of dementia (Hampel et al., 2004, 2003), in neurons with prominent dendritic ADDL binding (detected with NU1, Fig. 2K–M). ADDL binding to synaptic hot-spots in hippocampal neurons is evident in images at highermagnification (60×objective, PanelsLand M).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 22,
      "target": 18,
      "key": "52d9e13b0914a3f5445b3e88709aaeda535b671bd5d364b53fa6eb685118be27b82ba6a5ebaaaa31212f85290ae433adf1680852cd272eb271e035f09638cad7"
    },
    {
      "line": 240,
      "relation": "increases",
      "evidence": "AD brains could induce AD-type tau hyperphosphorylation. Consistent with the results obtained with synthetic ADDLs, we found that treatment of mature hippocampal neuronal cultures with a soluble AD brain extract led to a significant increase in P231 tau phosphorylation (Fig. 6D) compared to cultures treated with a non-AD brain extract (Fig. 6A).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 22,
      "target": 18,
      "key": "b2a85d6b59284d51931adc0fb089fdc9e0451acd394ec297a8cfc0809e99ed830df09bf65c1221e8d36e04495bf8d32912abbfc26a8084f6ebf2961901d9094b"
    },
    {
      "line": 239,
      "relation": "positiveCorrelation",
      "evidence": "AD brains could induce AD-type tau hyperphosphorylation. Consistent with the results obtained with synthetic ADDLs, we found that treatment of mature hippocampal neuronal cultures with a soluble AD brain extract led to a significant increase in P231 tau phosphorylation (Fig. 6D) compared to cultures treated with a non-AD brain extract (Fig. 6A).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 22,
      "target": 14,
      "key": "cbd82783082dd840df54f79a3d1855df6e9a3cf0757bedd54955a7cbebf92f86f8ec159feacc2f35693da9de6f00cc8c1291264c857da0c89794ed20e97bfdea"
    },
    {
      "relation": "hasComponent",
      "source": 10,
      "target": 1,
      "key": "75a3cf94d4d629a1279b03ee3f4b61a4c1c4c617146fe23d6ed8f2b3c617adef1dc1e5b3294f22d6be197769e4a7c7086473520c919fe5cf239893f61ab0d0a1"
    },
    {
      "relation": "hasComponent",
      "source": 10,
      "target": 3,
      "key": "9f50f8bddb1a78c3cabc7d9397f97afb77be88667f9fd1f6d1dc431f0e68b481df8727a32d495bf59fa0772ef9ce6cdd7acb4c6518226ada2531fdd885eb14ab"
    },
    {
      "line": 146,
      "relation": "increases",
      "evidence": "Hippocampal neurons exposed to Abeta fibrils rather than oligomers also showed elevated P-tau immunofluorescence (Fig. 2N–P) However, although fibrils could be seen attached to neurons, they did not bind in the synaptic pattern observed for ADDLs (Fig. 2O and P).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 4,
      "target": 15,
      "key": "e1a6ebe4b701ee0273d2384537c58f63458499f2730e5f6de505e026793225cd5472384301ac46ba59b23b35def551b0876102e9a2e4325c29080b4c16581708"
    },
    {
      "line": 159,
      "relation": "increases",
      "evidence": "Vehicle-treated neurons (Fig. 3A and E) exhibited very low phosphotau immunofluorescence, but neurons treated for 4 h with 500nM ADDLs showed significantly higher levels in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3B and F, respectively). Neurons treated for 4 h with 10\u0003M Abeta fibrils also showed an increase in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3C and G, respectively).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 4,
      "target": 18,
      "key": "7d860ed464d603bc944230707787337fdd42371a23b3b3908b1bec51b70ebd1a536bb91617626c8d1a356c35a2d97952e7a095239e5490a0dabf2cfec0a0adef"
    },
    {
      "line": 194,
      "relation": "increases",
      "evidence": "Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \u0003M Abeta fibrils (Fig. 4A–D).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 4,
      "target": 18,
      "key": "a691f353a5d769f9a96b0a6a47a1d03d173d28c1aa68abdf8b1dc5d04370429fd95bc3c9e9877b1276edcbf72771b8d0e45fe4a1d103a8d344f6404ea72f129d"
    },
    {
      "line": 160,
      "relation": "increases",
      "evidence": "Vehicle-treated neurons (Fig. 3A and E) exhibited very low phosphotau immunofluorescence, but neurons treated for 4 h with 500nM ADDLs showed significantly higher levels in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3B and F, respectively). Neurons treated for 4 h with 10\u0003M Abeta fibrils also showed an increase in immunofluorescence of P-Ser404 and P-Thr231 tau (Fig. 3C and G, respectively).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 4,
      "target": 16,
      "key": "dcd49f472ad3a2c296e43448b6f2aff1cb28c9d5ecca1e4dbbb9dab1401a10c9367055532352f08155620e7aee447c029f1cd253ccb02bae3bf7fc332b905132"
    },
    {
      "line": 195,
      "relation": "increases",
      "evidence": "Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \u0003M Abeta fibrils (Fig. 4A–D).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 4,
      "target": 16,
      "key": "b01efaccf7505dbc2b07e0b4b17c7838a12ef7500c633242bdd21711eae65f3b12d41067fb6624b7ae36de74f845e872e0bda2fbdec9d154bf3dac1ccdbab3ee"
    },
    {
      "line": 196,
      "relation": "increases",
      "evidence": "Verification of the findings from immunofluorescence microscopy was provided by Western blot analysis of hippocampal neuronal lysates with P404, P231 and P181 antiphosphotau antibodies. A 4 h exposure to 500nM ADDLs resulted in a significant increase in tau phosphorylated at the three epitopes, to levels similar to those observed after exposure to 10 \u0003M Abeta fibrils (Fig. 4A–D).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 4,
      "target": 17,
      "key": "607c099b2577079b5723f06b4533fb6357e2d3466a48256caf9e0227bd82317b0a19b355b4956be0bd6e0b58532cb7249aa936e486f28f3ec3a803e81988fef3"
    },
    {
      "line": 166,
      "relation": "decreases",
      "evidence": "NU1 completely blocked the increase in P-Ser404 and P-Thr231 phosphotau levels induced by ADDLs (Fig. 3D–H).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 2,
      "target": 3,
      "key": "5de31395f39c4d1a1d328b6e90ae52084a2040e1383baf617d9dbd6739cc0f8996ce66c6204650f4afc302810ef41fcc862e446ffc37b4e1d018e27cd5053ba0"
    },
    {
      "line": 227,
      "relation": "decreases",
      "evidence": "Moreover, the presence of large extracellular aggregates in NU1-treated cultures (Fig. 5N) suggests that the antibody effectively sequesters ADDLs and prevents their interactions with neurons (Fig. 5O). No inhibition of ADDL binding was associated with PP1 and LY294002 (Fig. 5H, I, K and L, respectively), but both kinase inhibitors effectively blocked ADDL-induced tau hyperphosphorylation (Fig. 5G and J).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 2,
      "target": 11,
      "key": "1c793f80a5fb3f33cd09f118420f2fde251843fb96658de606cf8ec44faec575038ebec6fadaa119144f93bc4939ac5b921172d0d10c75f1020c9cf3434286b7"
    },
    {
      "line": 257,
      "relation": "decreases",
      "evidence": "Importantly, pre-incubation of AD brain extracts with NU1 significantly blocked the increase in Thr231 phosphotau immunofluorescence (Fig. 6G), establishing the tau hyperphosphorylation was induced by Abeta oligomers in the AD brain extracts. NU1 also prevented the binding of brain-derived ADDLs to synaptic hot-spots (Fig. 6H and I). In NU1-treated cultures, the presence of large extracellular aggregates indicates that the antibody sequesters ADDLs and prevents their interactions with neurons (Fig. 6I).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 2,
      "target": 11,
      "key": "df5df1be4f6499759f962f736f9360e221cdc5d3020d423b2f04153baaf725ffaf38d7c9a6dbe57645afa10cb09f852fcbb506a71e9f7c456a17554dbb6f3a7e"
    },
    {
      "line": 255,
      "relation": "decreases",
      "evidence": "Importantly, pre-incubation of AD brain extracts with NU1 significantly blocked the increase in Thr231 phosphotau immunofluorescence (Fig. 6G), establishing the tau hyperphosphorylation was induced by Abeta oligomers in the AD brain extracts. NU1 also prevented the binding of brain-derived ADDLs to synaptic hot-spots (Fig. 6H and I). In NU1-treated cultures, the presence of large extracellular aggregates indicates that the antibody sequesters ADDLs and prevents their interactions with neurons (Fig. 6I).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 2,
      "target": 18,
      "key": "d2b00bda20e82aa93d1e5fb1793af717277bcf887ced574edc41646a3a6b899b53c465bc62eda5c2cccc41c53f3af14e3dc39da36d821a64ce07e6785536e7a7"
    },
    {
      "line": 258,
      "relation": "decreases",
      "evidence": "Importantly, pre-incubation of AD brain extracts with NU1 significantly blocked the increase in Thr231 phosphotau immunofluorescence (Fig. 6G), establishing the tau hyperphosphorylation was induced by Abeta oligomers in the AD brain extracts. NU1 also prevented the binding of brain-derived ADDLs to synaptic hot-spots (Fig. 6H and I). In NU1-treated cultures, the presence of large extracellular aggregates indicates that the antibody sequesters ADDLs and prevents their interactions with neurons (Fig. 6I).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 2,
      "target": 10,
      "key": "11ef61f09d0534ca1bd841c76b0849a44598294db28f060d289280b9d3e0a20b63806fb5934b343fd88396884c2066a9b53fb6a1efcbd01df287431a0b231da4"
    },
    {
      "line": 175,
      "relation": "increases",
      "evidence": "These results confirm that the tau hyperphosphorylation stimulated by soluble ADDL preparations is indeed oligomer-induced. Tau hyperphosphorylation induced by 10\u0003M Abeta fibrils (Fig. 3N) was partially blocked (Fig. 3O), consistent with shared epitopes between oligomers and fibrils.",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 5,
      "target": 14,
      "key": "98adb00058e611e55e7b0436fc3743e1d2bdd403b525c47dab98e626db9765d0eb1b7c75efad80f474abfb9786cc8c440311a86c7ea6b5d5e7cc8c9e8bd606ef"
    },
    {
      "line": 256,
      "relation": "increases",
      "evidence": "Importantly, pre-incubation of AD brain extracts with NU1 significantly blocked the increase in Thr231 phosphotau immunofluorescence (Fig. 6G), establishing the tau hyperphosphorylation was induced by Abeta oligomers in the AD brain extracts. NU1 also prevented the binding of brain-derived ADDLs to synaptic hot-spots (Fig. 6H and I). In NU1-treated cultures, the presence of large extracellular aggregates indicates that the antibody sequesters ADDLs and prevents their interactions with neurons (Fig. 6I).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 5,
      "target": 14,
      "key": "6d44eb07392b3ee6a62e0e8466426274e0bff403bf0fb4f2a98e27b9cfde8f4af491329edb9ac22ca75522241c13e649de3a13d26d008a11b9a974545ca162df"
    },
    {
      "line": 239,
      "relation": "positiveCorrelation",
      "evidence": "AD brains could induce AD-type tau hyperphosphorylation. Consistent with the results obtained with synthetic ADDLs, we found that treatment of mature hippocampal neuronal cultures with a soluble AD brain extract led to a significant increase in P231 tau phosphorylation (Fig. 6D) compared to cultures treated with a non-AD brain extract (Fig. 6A).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 14,
      "target": 22,
      "key": "3b12f88b8a28992d4757e5eeff1bc1016782cefb1bc43df9ea49cf8543eb4da3362399ed8b01086e9cbc12dd387be06bc2757ea22ed3a57ac9a490984750bb2a"
    },
    {
      "line": 181,
      "relation": "positiveCorrelation",
      "evidence": "We note that these observed increases in tau phosphorylation occurred well before neuronal death (Fig. 1B), consistent with this pathology representing an early stage in neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 21,
      "target": 15,
      "key": "95ab44bb1283735dffbf3a7781829b2830a36ddf05de0be8fae5498eca344a27532c23765c0c843345977cf273f903a1c5fe2052079ff418564252d6a10f2e13"
    },
    {
      "line": 205,
      "relation": "decreases",
      "evidence": "Interestingly, we found that tau hyperphosphorylation at Thr231 was completely blocked by the Src family tyrosine kinase inhibitor, 4-amino-5-(4- chlorophenyl)-7(t-butyl)pyrazol(3,4-d)pyramide (PP1), and by the phosphatidylinositol 3-kinase inhibitor, LY294002 (Fig. 5).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 6,
      "target": 18,
      "key": "e7257beb1630bf1d3c449b24cf85159461996820595bd27ef81282fb0baa294a4dfdda97a403dd25f134f2dbc189ebd71a635c659db8a78d3363e56fd3cba7d1"
    },
    {
      "line": 214,
      "relation": "decreases",
      "evidence": "Inhibition occurred even though ADDLs were still bound to cell surfaces, indicating that those kinases are involved in signal transduction coupling between ADDL binding and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 6,
      "target": 8,
      "key": "4a6e060360a3714a8a86881e00fd8c85bb704a4d61e906b4dc4114a3ef256aed98c85c646e8fae2efba45cd83e5eb8caceaaaf57ef0e5312f16d47f9019c10b8"
    },
    {
      "line": 228,
      "relation": "decreases",
      "evidence": "Moreover, the presence of large extracellular aggregates in NU1-treated cultures (Fig. 5N) suggests that the antibody effectively sequesters ADDLs and prevents their interactions with neurons (Fig. 5O). No inhibition of ADDL binding was associated with PP1 and LY294002 (Fig. 5H, I, K and L, respectively), but both kinase inhibitors effectively blocked ADDL-induced tau hyperphosphorylation (Fig. 5G and J).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 6,
      "target": 14,
      "key": "bb60f356ba27aac6b4fe55a3d2963ac75bd828b0ea1d3fb5c632f46f54acc6a35283f2a5be02ce5db6c5e49492a42f81d3422985c25e60b1157a2b8a7a00800c"
    },
    {
      "line": 206,
      "relation": "decreases",
      "evidence": "Interestingly, we found that tau hyperphosphorylation at Thr231 was completely blocked by the Src family tyrosine kinase inhibitor, 4-amino-5-(4- chlorophenyl)-7(t-butyl)pyrazol(3,4-d)pyramide (PP1), and by the phosphatidylinositol 3-kinase inhibitor, LY294002 (Fig. 5).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 0,
      "target": 18,
      "key": "338f50b8d62deb4deb32873a3e8de1dd97709050c632d916f0ff4518f2dcc207a486ce8b441ad0c9250680e510008b593fef7a5d92e6e2d20ae59cc1ee2182e3"
    },
    {
      "line": 213,
      "relation": "decreases",
      "evidence": "Inhibition occurred even though ADDLs were still bound to cell surfaces, indicating that those kinases are involved in signal transduction coupling between ADDL binding and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 0,
      "target": 8,
      "key": "9e950d8e99ba84ae271625a4140cc926541113cca5483c7e97aa65fd1b7d1ab0b763efc158cacd7aa9b825546ae81d620059e3e802e42e522e4e05d1b8ffa9bd"
    },
    {
      "line": 229,
      "relation": "decreases",
      "evidence": "Moreover, the presence of large extracellular aggregates in NU1-treated cultures (Fig. 5N) suggests that the antibody effectively sequesters ADDLs and prevents their interactions with neurons (Fig. 5O). No inhibition of ADDL binding was associated with PP1 and LY294002 (Fig. 5H, I, K and L, respectively), but both kinase inhibitors effectively blocked ADDL-induced tau hyperphosphorylation (Fig. 5G and J).",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 0,
      "target": 14,
      "key": "79e5ce4b341990b15a90ac4b868c12bb7d467cef8a9fb2a0ad5aed5c0a8f7499c5a3d7016b74df285b5851a826320228db55136c66f4760f126400b6f85ffbf1"
    },
    {
      "line": 215,
      "relation": "increases",
      "evidence": "Inhibition occurred even though ADDLs were still bound to cell surfaces, indicating that those kinases are involved in signal transduction coupling between ADDL binding and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 8,
      "target": 12,
      "key": "807bd7041144a928e6fd9e995422953d622b1b131131e7d3ed6510ad4403c5cbe04b4d56a8d27d90f538292290bf0f709a4c36b88b6f35a1d38f455d2fc98b92"
    },
    {
      "relation": "hasComponent",
      "source": 12,
      "target": 3,
      "key": "40b6dc3f994da756b65aadc31878888c88b15448d22952dd5cda9a5155e1cca08828103d3fa4987a6a3594ecc0b9898541ec89948214c16d8788290c60a12278"
    },
    {
      "relation": "hasComponent",
      "source": 12,
      "target": 13,
      "key": "a7703d70712731448b5e962ef60decaf22ebd3c951eda597b1975176d4d608acc7bd3bb30cca04f114d84205d5a337fa7650501e9b6f5caaa3d689f125c68c51"
    },
    {
      "line": 216,
      "relation": "increases",
      "evidence": "Inhibition occurred even though ADDLs were still bound to cell surfaces, indicating that those kinases are involved in signal transduction coupling between ADDL binding and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "17403556"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        }
      },
      "source": 12,
      "target": 14,
      "key": "899b6377b06dc8dd2ca9142f873c9c1aa3322033962d4fe1cdac6b4b175dd202eea7f917958cfdbf6a0d74529be7779897161cb13cae4e405c9006fe3dded77a"
    },
    {
      "relation": "hasComponent",
      "source": 11,
      "target": 3,
      "key": "43a11b05ce34e7353cab2cee6a2fc2deb049eaf003b62855720d405cea01db8dd343f3931316ada9dcfc8626b8b9ae45f454ede54def292e2795712c62a3d52b"
    },
    {
      "relation": "hasComponent",
      "source": 11,
      "target": 7,
      "key": "6f83c3f0c80caa432d381b9b381d6167a14821d0acde804b4f6e77e0d113f3dc73f1ae9e3c2892eb03d6439a9f15d03af4edec8058cd41684583c3d6ad5dd667"
    }
  ]
}